Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 May;41(5):1146–1149. doi: 10.1128/aac.41.5.1146

Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.

H P Endtz 1, J W Mouton 1, J G den Hollander 1, N van den Braak 1, H A Verbrugh 1
PMCID: PMC163867  PMID: 9145886

Abstract

The in vitro activity of trovafloxacin (CP-99,219), a new fluoroquinolone, was compared with the in vitro activities of other commonly used quinolones and other antimicrobial agents against 445 gram-positive microorganisms isolated between 1986 and 1995 from patients with endocarditis and those with other bloodstream infections. The MICs at which 90% of the isolates are inhibited (MIC90) of trovafloxacin for methicillin-susceptible staphylococci, viridans group streptococci, and enterococci were 0.06, 0.25, and 0.5 mg/liter, respectively. The MIC90 of trovafloxacin for vancomycin-resistant enterococci as well as for methicillin-resistant Staphylococcus aureus and methicillin-susceptible and ciprofloxacin-resistant S. aureus, isolated from sources other than blood, was 1 mg/liter. For the quinolones the rank order of activity was trovafloxacin > sparfloxacin > ciprofloxacin = ofloxacin > pefloxacin. Depending on the species tested, trovafloxacin was 4- to 64-fold more active than ciprofloxacin. Further experimental and in vivo studies are warranted to evaluate the efficacy of trovafloxacin in the treatment of bacterial endocarditis and other infections caused by gram-positive organisms.

Full Text

The Full Text of this article is available as a PDF (225.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Brown S. D., Fuchs P. C. In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219) -letter-. J Antimicrob Chemother. 1996 Aug;38(2):324–327. doi: 10.1093/jac/38.2.324. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Fuchs P. C. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother. 1991 May;35(5):955–960. doi: 10.1128/aac.35.5.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bourgault A. M., Wilson W. R., Washington J. A., 2nd Antimicrobial susceptibilities of species of viridans streptococci. J Infect Dis. 1979 Sep;140(3):316–321. doi: 10.1093/infdis/140.3.316. [DOI] [PubMed] [Google Scholar]
  4. Carratalá J., Alcaide F., Fernández-Sevilla A., Corbella X., Lińares J., Gudiol F. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis. 1995 May;20(5):1169–1173. doi: 10.1093/clinids/20.5.1169. [DOI] [PubMed] [Google Scholar]
  5. Chin N. X., Figueredo V. M., Novelli A., Neu H. C. In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):58–63. doi: 10.1007/BF01962176. [DOI] [PubMed] [Google Scholar]
  6. Coque T. M., Singh K. V., Murray B. E. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci. J Antimicrob Chemother. 1996 May;37(5):1011–1016. doi: 10.1093/jac/37.5.1011. [DOI] [PubMed] [Google Scholar]
  7. Cormican M. G., Jones R. N. In-vitro activity of trovafloxacin (CP99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates. J Antimicrob Chemother. 1996 Apr;37(4):847–849. doi: 10.1093/jac/37.4.847. [DOI] [PubMed] [Google Scholar]
  8. Doern G. V., Ferraro M. J., Brueggemann A. B., Ruoff K. L. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother. 1996 Apr;40(4):891–894. doi: 10.1128/aac.40.4.891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Domagala J. M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother. 1994 Apr;33(4):685–706. doi: 10.1093/jac/33.4.685. [DOI] [PubMed] [Google Scholar]
  10. Dworkin R. J., Lee B. L., Sande M. A., Chambers H. F. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet. 1989 Nov 4;2(8671):1071–1073. doi: 10.1016/s0140-6736(89)91083-0. [DOI] [PubMed] [Google Scholar]
  11. Eliopoulos G. M., Klimm K., Eliopoulos C. T., Ferraro M. J., Moellering R. C., Jr In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993 Feb;37(2):366–370. doi: 10.1128/aac.37.2.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Entenza J. M., Blatter M., Glauser M. P., Moreillon P. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Antimicrob Agents Chemother. 1994 Dec;38(12):2683–2688. doi: 10.1128/aac.38.12.2683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Giamarellou H. Activity of quinolones against gram-positive cocci: clinical features. Drugs. 1995;49 (Suppl 2):58–66. doi: 10.2165/00003495-199500492-00010. [DOI] [PubMed] [Google Scholar]
  14. Gootz T. D., Brighty K. E., Anderson M. R., Schmieder B. J., Haskell S. L., Sutcliffe J. A., Castaldi M. J., McGuirk P. R. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagn Microbiol Infect Dis. 1994 Aug;19(4):235–243. doi: 10.1016/0732-8893(94)90037-x. [DOI] [PubMed] [Google Scholar]
  15. Gootz T. D., Zaniewski R., Haskell S., Schmieder B., Tankovic J., Girard D., Courvalin P., Polzer R. J. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother. 1996 Dec;40(12):2691–2697. doi: 10.1128/aac.40.12.2691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Guiot H. F., Corel L. J., Vossen J. M. Prevalence of penicillin-resistant viridans streptococci in healthy children and in patients with malignant haematological disorders. Eur J Clin Microbiol Infect Dis. 1994 Aug;13(8):645–650. doi: 10.1007/BF01973990. [DOI] [PubMed] [Google Scholar]
  17. Heldman A. W., Hartert T. V., Ray S. C., Daoud E. G., Kowalski T. E., Pompili V. J., Sisson S. D., Tidmore W. C., vom Eigen K. A., Goodman S. N. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med. 1996 Jul;101(1):68–76. doi: 10.1016/s0002-9343(96)00070-8. [DOI] [PubMed] [Google Scholar]
  18. Qadri S. M., Ueno Y. Antibacterial activity of trovafloxacin against gram-positive blood culture isolates from nosocomial infections. Eur J Clin Microbiol Infect Dis. 1996 Aug;15(8):694–696. doi: 10.1007/BF01691163. [DOI] [PubMed] [Google Scholar]
  19. Quale J. M., Landman D., Mobarakai N. Treatment of experimental endocarditis due to multidrug resistant Enterococcus faecium with ciprofloxacin and novobiocin. J Antimicrob Chemother. 1994 Nov;34(5):797–802. doi: 10.1093/jac/34.5.797. [DOI] [PubMed] [Google Scholar]
  20. Tebas P., Martinez Ruiz R., Roman F., Mendaza P., Rodriguez Diaz J. C., Daza R., de Letona J. M. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J Infect Dis. 1991 Jan;163(1):204–205. doi: 10.1093/infdis/163.1.204-a. [DOI] [PubMed] [Google Scholar]
  21. Whitman M. S., Pitsakis P. G., Zausner A., Livornese L. L., Osborne A. J., Johnson C. C., Levison M. E. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1993 Oct;37(10):2069–2073. doi: 10.1128/aac.37.10.2069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Zaman M. M., Landman D., Burney S., Quale J. M. Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with clinafloxacin and penicillin. J Antimicrob Chemother. 1996 Jan;37(1):127–132. doi: 10.1093/jac/37.1.127. [DOI] [PubMed] [Google Scholar]
  24. van der Meer J. T., van Vianen W., Hu E., van Leeuwen W. B., Valkenburg H. A., Thompson J., Michel M. F. Distribution, antibiotic susceptibility and tolerance of bacterial isolates in culture-positive cases of endocarditis in The Netherlands. Eur J Clin Microbiol Infect Dis. 1991 Sep;10(9):728–734. doi: 10.1007/BF01972497. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES